NASDAQ | VICL: 1.31  +0.00
investors
Investors

News Releases

DateSubject
November 2, 2011 Vical to Present at Credit Suisse 2011 Healthcare Conference
November 1, 2011 Vical Reports Third Quarter 2011 Financial Results and Progress in Key Development Programs
October 25, 2011 Vical Announces News Release and Conference Call Schedule for Third Quarter 2011 Financial Results
October 17, 2011 Vical to Present at NewsMakers Conference
October 3, 2011 Vical Reports Prophylactic and Therapeutic Efficacy With Herpes Simplex Vaccines in Guinea Pig Model
September 22, 2011 Allovectin(R) Demonstrates Synergistic Efficacy With Anti-CTLA-4 Antibody in Melanoma Animal Model
September 19, 2011 Vical Announces Key International Patents for Vaxfectin(R) Adjuvant
August 31, 2011 Vical to Present at September Investor Conferences
August 17, 2011 Vical Provides Vaxfectin(R) Review at Novel Vaccines: Adjuvants & Delivery Systems Conference
August 8, 2011 Vical to Present at Canaccord Genuity Growth Conference
August 3, 2011 Vical Reports Second Quarter 2011 Financial Results and Progress in Key Development Programs
July 27, 2011 Vical Announces News Release and Conference Call Schedule for Second Quarter 2011 Financial Results
July 25, 2011 Vical Announces Early Termination of Hart-Scott-Rodino Waiting Period for TransVax(TM) License Agreements With Astellas
July 21, 2011 Vical Reports Successful Nonclinical Results With Vaxfectin(R) Adjuvant
July 14, 2011 Vical and Astellas Announce Worldwide License Agreements for TransVax(TM) Cytomegalovirus Vaccine
July 14, 2011 Vical Announces Scientific Advances for Multiple Programs at DNA Vaccines 2011 Conference
June 28, 2011 Vical Provides Allovectin(R) and Herpes Simplex Vaccine Updates at BIO International Convention
June 6, 2011 Vical Presents Positive Correlation Between Response and Survival at ASCO for Completed Allovectin(R) Melanoma Trials
June 2, 2011 Vical to Present at Jefferies Global Healthcare Conference
May 19, 2011 Vical Presentations on TransVax(TM) and DNA Vaccines at ASGCT Conference
May 16, 2011 Presentations by Vical and Collaborators at CMV/BetaHerpesvirus Workshop
May 10, 2011 Vical to Present at Noble Financial Capital Markets Conference
May 9, 2011 Vical to Present at Bank of America/Merrill Lynch Health Care Conference
May 5, 2011 Vical Reports First Quarter 2011 Financial Results and Progress in TransVax(TM) and Allovectin(R) Programs
May 4, 2011 Vical and the University of Washington Receive Additional U.S. Patent for Herpes Simplex Vaccine
April 28, 2011 Vical Announces News Release and Conference Call Schedule for First Quarter 2011 Financial Results
April 27, 2011 Vical Announces Encouraging H1N1 Pandemic Influenza Vaccine Phase 1 Results
April 14, 2011 Vical Announces Key European Patent for TransVax(TM) Cytomegalovirus Vaccine
March 31, 2011 Vical to Participate in Leerink Swann Cancer Roundtable Conference
March 14, 2011 Vical to Present at ROTH Growth Stock Conference
March 2, 2011 Vical Receives Positive Scientific Advice From EMA for TransVax(TM) Phase 3 Trial
February 24, 2011 Vical to Present at Upcoming Investor Conferences
February 22, 2011 Vical Extends Collaboration With U.S. Government for Emerging Disease Vaccines
February 16, 2011 Vical Receives U.S. Patent for Cytomegalovirus Vaccines
February 14, 2011 Vical's Allovectin-7(R) Phase 3 Trial Receives Positive Review from Safety Monitoring Board
February 10, 2011 Vical Reports 2010 Financial Results and Progress in Key Development Programs
February 8, 2011 Vical and the University of Washington Receive U.S. Patent for Herpes Simplex Vaccine
February 3, 2011 Vical Announces News Release and Conference Call Schedule for 2010 Financial Results
January 11, 2011 Publication Highlights Allovectin-7(R) Phase 2 Safety and Efficacy Results in Melanoma

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.